Edwards Lifesciences Corp [EW] stock is trading at $73.32, down -0.88%. An important factor to consider is whether the stock is rising or falling in short-term value. The EW shares have gain 2.50% over the last week, with a monthly amount glided 10.22%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Jefferies downgraded its rating to Hold on September 18, 2024, and dropped its price target to $70. On July 31, 2024, upgrade upgraded it’s rating to Outperform. Wolfe Research upgraded its rating to a Peer Perform. Truist downgraded its rating to a Hold and reduced its price target to $82 on July 25, 2024. TD Cowen downgraded its rating to Hold for this stock on July 25, 2024, and downed its price target to $70. In a note dated July 25, 2024, Robert W. Baird downgraded an Neutral rating on this stock and revised its target price from $102 to $70.
Edwards Lifesciences Corp [EW] stock has fluctuated between $58.93 and $96.12 over the past year. Currently, Wall Street analysts expect the stock to reach $76.33 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $73.32 at the most recent close of the market. An investor can expect a potential return of 4.11% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 5.87B for the trailing twelve months, which represents a drop of -8.54%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.27%, Pretax Profit Margin comes in at 0.28%, and Net Profit Margin reading is 0.71%. To continue investigating profitability, this company’s Return on Assets is posted at 0.32, Equity is 0.54 and Total Capital is 0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 72.45 points at the first support level, and at 71.57 for the second support level. However, for the 1st resistance point, the stock is sitting at 74.24, and for the 2nd resistance point, it is at 75.15.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 3.46. On the other hand, the Quick Ratio is 2.89, and the Cash Ratio is 1.89. Considering the valuation of this stock, the price to sales ratio is 7.30, the price to book ratio is 4.53 and price to earnings (TTM) ratio is 10.58.
Transactions by insiders
Recent insider trading involved Ullem Scott B., CVP, Chief Financial Officer, that happened on Dec 09 ’24 when 11250.0 shares were sold. CVP,Strategy/Corp Development, BOBO DONALD E JR completed a deal on Dec 09 ’24 to sell 5000.0 shares. Meanwhile, Officer Ullem Scott B. bought 33750.0 shares on Dec 09 ’24.
